PCI Biotech Holding ASA
OSE:PCIB

Watchlist Manager
PCI Biotech Holding ASA Logo
PCI Biotech Holding ASA
OSE:PCIB
Watchlist
Price: 0.242 NOK -1.63% Market Closed
Market Cap: 9m NOK

PCI Biotech Holding ASA
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

PCI Biotech Holding ASA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
PCI Biotech Holding ASA
OSE:PCIB
Operating Income
-kr21.6m
CAGR 3-Years
36%
CAGR 5-Years
23%
CAGR 10-Years
4%
Hofseth Biocare ASA
OSE:HBC
Operating Income
-kr111.6m
CAGR 3-Years
5%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Arcticzymes Technologies ASA
OSE:AZT
Operating Income
-kr7.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
8%
N
Nykode Therapeutics ASA
OSE:NYKD
Operating Income
-$26.5m
CAGR 3-Years
-3%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Operating Income
-kr33.3m
CAGR 3-Years
58%
CAGR 5-Years
41%
CAGR 10-Years
13%
Zelluna ASA
OSE:ZLNA
Operating Income
-kr217.5m
CAGR 3-Years
-11%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
No Stocks Found

PCI Biotech Holding ASA
Glance View

Market Cap
9m NOK
Industry
Biotechnology

PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo. The company went IPO on 2008-06-18. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Company’s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. The company focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.

PCIB Intrinsic Value
1.575 NOK
Undervaluation 85%
Intrinsic Value
Price

See Also

What is PCI Biotech Holding ASA's Operating Income?
Operating Income
-21.6m NOK

Based on the financial report for Jun 30, 2025, PCI Biotech Holding ASA's Operating Income amounts to -21.6m NOK.

What is PCI Biotech Holding ASA's Operating Income growth rate?
Operating Income CAGR 10Y
4%

Over the last year, the Operating Income growth was 29%. The average annual Operating Income growth rates for PCI Biotech Holding ASA have been 36% over the past three years , 23% over the past five years , and 4% over the past ten years .

Back to Top